Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Entrada Therapeutics (TRDA) Payables: 2022-2024

Historic Payables for Entrada Therapeutics (TRDA) over the last 3 years, with Dec 2024 value amounting to $4.3 million.

  • Entrada Therapeutics' Payables rose 145.05% to $3.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.5 million, marking a year-over-year increase of 31.37%. This contributed to the annual value of $4.3 million for FY2024, which is 29.97% up from last year.
  • Latest data reveals that Entrada Therapeutics reported Payables of $4.3 million as of FY2024, which was up 29.97% from $3.3 million recorded in FY2023.
  • In the past 5 years, Entrada Therapeutics' Payables ranged from a high of $6.0 million in FY2022 and a low of $3.3 million during FY2023.
  • Moreover, its 3-year median value for Payables was $4.3 million (2024), whereas its average is $4.5 million.
  • Per our database at Business Quant, Entrada Therapeutics' Payables slumped by 45.29% in 2023 and then increased by 29.97% in 2024.
  • Yearly analysis of 3 years shows Entrada Therapeutics' Payables stood at $6.0 million in 2022, then plummeted by 45.29% to $3.3 million in 2023, then grew by 29.97% to $4.3 million in 2024.